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ABSTRACT
Although autologous stem cell transplantation (ASCT) for patients with relapsed/refractory Hodgkin lym-
phoma (HL) appears to offer a survival advantage over conventional therapy, only approximately 25% to 35%
of patients with primary progressive or poor-risk recurrent HL can achieve durable remission after ASCT, with
disease progressive after transplant accounting for most of the treatment failures. We conducted a pilot study
to evaluate the toxicities and efficacy of a tandem transplant approach in this subgroup of patients. Between
April 1998 andMarch 2000, 46 patients were enrolled in the study. Eligibility criteria: primary progressive (n
28) or recurrent HL (n  18) with at least 1 of the following poor prognostic factors: first complete remission
(CR) <12 months (n  15) or extra-nodal disease (n  4) or B symptoms at relapse (n  4). The first cycle
consisted of melphalan (150 mg/m2) alone. The second cycle consisted of fractionated total body irradiation
(FTBI) 1200 cGy or BCNU (450 mg/m2) in combination with etoposide (60 mg/kg) and cyclophosphamide
(100 mg/kg). Of the 46 patients, 5 (11%) did not receive the planned tandem transplants because of inadequate
stem cell collection for 2 ASCT. After a median of 64 days (25-105), 41 patients received the second ASCT.
With a median follow-up of 5.3 years (1.6-8.1), the 5-year estimate of overall survival, progression-free survival,
and freedom from progression were 54% (95% confidence interval [CI] 40%-69%), 49% (95% CI, 34%-63%),
and 55% (95%CI, 40%-70%), respectively. Our mature results from this study suggest that in patients with
primary progressive or poor risk recurrent HL, this tandem ASCT program is effective and well tolerated and
compares favorably with the conventional single transplant.
© 2007 American Society for Blood and Marrow Transplantation
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tNTRODUCTION
Combination chemotherapy with or without radi-
tion can cure 60% to 70% of patients with advanced
tage Hodgkin lymphoma (HL) [1]. For patients who
evelop disease progression during induction or
ithin 12 months after completion of treatment, the
rognosis is poor. In a long-term follow-up report
rom Milan Cancer Institute, the 8-year overall sur-
ival (OS) rate was 8% for patients who failed to
chieve complete remission after nitrogen mustard,
incristine, procarbazine, prednisone, adriamycin, bleo-
ycin, vinblastine and dacarbazine (MOPP-ABVD) r
942]. Relapses after longer initial remissions (ie, 12
onths or greater) are more amenable to conven-
ional dose salvage treatment [2]. However, in a long-
erm follow-up report from the National Cancer In-
titute, the OS was only 24% among patients with
ong initial remission after retreatment with MOPP
hemotherapy [3]. Based on the evolving maturing
ata from multiple phase II studies and 2 prospective
hase III studies, autologous stem cell transplantation
ASCT) is becoming the preferred treatment for pa-
ients who fail to achieve a remission with conven-
ional therapy or who relapse after achieving an initial
emission. The results from single institution studies
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Tandem Autologous Stem Cell Transplantation 5954-6], as well as cooperative group trials [7], have
ndicated that various high-dose regimens can result
n disease-free survival rates of 30% to 65% in pa-
ients who failed their initial treatment. Although
hese results represent a signiﬁcant improvement over
hose obtained with conventional therapy, up to 50%
f patients still relapse after ASCT.
Multiple transplant studies have attempted to
dentify prognostic factors to predict transplant out-
omes [4-8]. Failure to achieve an initial clinical re-
ission or a short initial remission is the most com-
only reported unfavorable prognostic factors. The
stimated probability of long-term progression-free
urvival after transplant was approximately 25% to
5% for patients with primary refractory or poor risk
ecurrent HL. Conversely, the best results after au-
ografts are seen in patents with a complete remission
o salvage therapy [6,7,9]. Based on these studies, we
ypothesized that transplant outcome could be im-
roved if a minimal disease state can be achieved in a
igher number of patients before the “conventional”
ransplant. We designed a tandem transplant program
sing high-dose melphalan with stem cell support
cycle I) followed by a planned second high dose
herapy with stem cell rescue (cycle 2) [5,7].
ATIENTS AND METHODS
Between April 1998 and March 2000, 46 patients
articipated in this pilot study through the collabora-
ion between City of Hope Comprehensive Cancer
enter and Loyola University Medical Center. Both
articipating institutions’ review boards approved the
rotocol. Eligibility criteria: patients with the follow-
ng characteristics were eligible for the study: biopsy-
roved Hodgkin lymphoma; aged 15-65 years, with
rimary refractory disease deﬁned as progressive dis-
ase while on therapy, relapse within 3 months after
ompletion of treatment or less than a partial response
o initial therapy; or relapsed disease associated with 1
r more of the following poor risk features: extra-
odal disease or B symptoms at relapse, chemorefrac-
ory disease, and duration of ﬁrst response of 12
onths. Speciﬁcally, patients who relapsed12 months
fter the completion of initial chemotherapy and who
esponded to salvage therapy were excluded. Eligible
atients needed to have a normal cardiac ejection
raction of 50%, FEV1 60% or DLCO 50%
redicted, creatinine clearance 60 mL/min, normal
one marrow examination by morphology, and a nor-
al cytogenetic study, negative HIV testing, and no
vidence of active hepatitis infection with SGOT and
GPT 2 times of upper limit of normal.
reatment Plan
Patients who fulﬁlled the criteria for entry re-
eived high-dose etoposide 1 gm/m2 in combination aith cyclophosphamide 1.5 gm/m2 for cytoreduction
nd stem cell mobilization. Granulocyte-colony stim-
lating factor (G-CSF) was started after chemother-
py followed by stem cell collection. In patients who
lready had good response to salvage chemotherapy,
tem cells were collected after last cycles of salvage
herapy. The minimum target number of CD 34
ells was 5  106/kg. Restaging with CT and if pos-
ible PET or gallium scans were performed before
ach transplant. The ﬁrst cycle of high-dose therapy
onsisted of a single 1-hour infusion of melphalan
150 mg/m2) and stem cells were infused 24-48 hours
ater. After recovery, the second high dose cycle was
iven (minimum 28 days between cycles). The second
ycle consisted of total body irradiation (TBI) 1200
Gy in 8-10 divided doses given over 4 days in com-
ination with high-dose etoposide (60 mg/kg, adjusted
ody weight) and cyclophosphamide (100 mg/kg,
deal body weight). For patients who had received
rior dose-limiting radiation, we substituted BCNU
450 mg/m2) for TBI. A minimum of 2  106 CD
4-positive autologous stem cells were reinfused after
ach cycle of therapy. All patients received growth
actor support, G-CSF after ASCT. All blood product
ransfusions were irradiated and ﬁltered. Platelet and
ed blood cells transfusions were given to maintain
latelets above 20,000 per L and hematocrit above
5%. All patients received standard antibiotics pro-
hylaxis with a quinolone and ﬂuconazole for antifun-
al prophylaxis. Patients who were seropositive for
erpes simplex also received acyclovir prophylaxis.
tatistical Analyses
Demographic and disease characteristics were
ummarized for all patients using descriptive statistics.
urvival estimates were calculated based on the product-
imit method, and 95% conﬁdence intervals were
alculated using the logit transformation with Green-
ood’s variance estimate. Factors possibly associated
ith overall survival, event-free survival, and freedom
rom progression were examined by univariate Cox
egression analysis. The assumption of proportionality
f the hazard ratio was tested for each variable. The
ariables tested included age, sex, stage at diagnosis
I/II versus III versus IV), “B” symptoms or extra-
odal disease at diagnosis and relapse, number of prior
hemotherapy regimens, prior radiation therapy, dis-
ase status (primary refractory versus relapsed), che-
osensitivity, interval between cycle 1 and cycle 2
igh-dose therapy, and conditioning regimen (TBI
ersus BCNU). The risk ratio was calculated for each
ariable, along with the 95% conﬁdence limits. Mul-
ivariate analyses were not performed because of the
mall number of patients in the study.
In this study, disease progression and death from
ny cause deﬁned events in the calculation of event
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H. C. Fung et al.596ree survival. Progression of Hodgkin lymphoma was
he only event deﬁned in freedom from progression:
oxic death and second malignancies were censored.
ESULTS
The patient characteristics are shown in Table 1.
he median age at transplant was 37 (range: 17-65)
nd 27 patients (59%) were male. The initial staging
ere stage I/II in 18 (39%), III in 21 (46%), and IV in
(15%). Twenty-four (52%) patients had “B” symp-
oms at diagnosis. Induction chemotherapy consisted
able 1. Patient Characteristics (n  46)
ge at transplant (years)
Median (range) 37 (17–65)
ex
Male 27 (59%)
Female 19 (41%)
tage at Dx
I/II 18 (39%)
III 20 (46%)
IV 8 (15%)
B” Symptoms at Dx
Yes 24 (52%)
No 22 (48%)
nduction chemotherapy
ABVD 30 (65%)
MOPP/ABVD, MOPP/ABV 9 (19%)
Stanford V 3 (7%)
Other 4 (9%)
nduction radiotherapy
Yes 19 (41%)
eason for tandem transplant
Primary refractory 28 (61%)
Poor risk recurrent 18 (39%)
isease status at ASCT
Relapsed 16 (35%)
Induction failure 30 (65%)
hemosensitivity
Chemoresistant 7 (15%)
Chemosensitive 22 (48%)
Not tested 17 (37%)
alvage chemotherapy
Yes 29 (63%)
High-dose etoposide  cyclophosphamide 17 (37%)
xtranodal involvement at ASCT
Yes 17 (37%)
No 29 (63%)
tage at ASCT
I/II 20 (43%)
III/IV 20 (44%)
Remission 6 (13%)
B” Symptoms at ASCT
Yes 9 (19%)
No 37 (81%)
nvolved Radiation Posttransplant
Yes 7 (15%)
BVD indicates adriamycin, bleomycin, vinblastine, dacarbazine;
MOPP, nitrogen mustard, vincristine, procarbazine, and pred-
nisone; MOPP/ABV, nitrogen mustard, vincristine, procarba-
zine, prednisone, adriamycin, bleomycin, and vinblastine;aASCT, autologous stem cell transplant.f ABVD in 30 (65%), MOPP/ABVD in 7 (15%),
OPP/ABV hybrid in 2 (4%), Stanford V in 3 (7%),
nd others in 4 (9%). Twenty-eight patients (61%)
ad primary refractory disease and 18 (39%) had poor
isk recurrent HL. Among the 28 patients with pri-
ary refractory HL, 11 progressed while receiving
heir initial induction chemotherapy, 15 achieved a
ransient complete/partial remission but progressed
ithin 90 days after the end of treatment, and 2 had
chieved partial remission with residual disease docu-
ented by CAT scan and FDG PET scan. Among the
8 relapsed patients, 15 had the duration of ﬁrst re-
ission 12 months, 4 had extra-nodal disease at
elapse, 4 had B symptoms at relapse, and 3 had
hemorefractory disease. Seven of the 18 had more
han 1 poor risk features.
alvage Therapy
Although it was not our intention to test for the
hemosensitivity before transplant, 29 patients re-
eived some form of salvage therapy before transplant
nd 7 patients were found to have chemorefractory
isease. The other 17 patients received high-dose eto-
oside and cyclophosphamide for cytoreduction and
tem cell mobilization as per protocol. None of the
atients received salvage radiotherapy before trans-
lant.
ransplantation
Five patients (11%) who consented and were en-
olled in the study did not receive the planned tandem
ransplant. Four had inadequate stem cell collections
or 2 ASCT and 1 withdrew consent before the ﬁrst
ycle of high-dose therapy. Of these 5 patients, 3 went
n to receive a single cycle conventional ASCT, 1
eceived an allogeneic stem cell transplant, and the
ther received conventional salvage treatment. Cur-
ently, 3 of these 5 patients are alive and progression
ree at last follow-up, whereas the other 2 patients
eveloped disease progression.
Of the 41 patients who received the planned ﬁrst
ycle of high-dose therapy, 5 developed disease pro-
ression before receiving the second high-dose ther-
py. Four proceeded to receive the second cycle of
igh-dose as planned, but all developed disease pro-
ression after the second ASCT. One patient who
lected to receive an allogeneic stem cell transplant
lso relapsed after that transplant. The other 36 pa-
ients, all responded to high-dose melphalan based on
T scan; 18 of these had gallium or FDG PET before
he second transplant and 5 continued to have positive
allium scans or FDG PET.
At a median of 64 days (range: 25-105), 41 patients
eceived the second high-dose therapy and ASCT.
wenty-ﬁve patients received FTBI-based regimen
nd 16 received BCNU-based regimen. Seven pa-
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Tandem Autologous Stem Cell Transplantation 597ients received involved radiotherapy 24-36 Gy to
esidual bulky mass 5 cm at 4-6 weeks after recovery
rom second high-dose except 1 who received before
he second transplant. For the 5 patients with positive
allium/FDG PET before second SCT, 4 are still
live in remission and 1 died from adenocarcinoma of
iver at 1 year after transplant. Two received involved-
eld radiation to residual bulky mass (neck/media-
timun 1, and minimantle 1) posttransplant.
ematopoietic Recovery
All patients had achieved hematopoietic recovery
ost the ﬁrst and the second high-dose treatment. The
edian day to reach absolute neutrophil count of 500
nd platelet count of 20,000/L were 10 days (range:
-14), and 11 days (range: 10-13), respectively, after
igh-dose melphalan, and 12 days (range: 10-14) and
4 days (range: 10-19), respectively, after the second
igh-dose therapy. There was no statistically signiﬁ-
ant difference between the engraftment following the
rst and the second high-dose treatment.
urvival
With a median follow-up of 5.3 years (range: 1.6-
.1 years), 21 (46%) patients are alive and progres-
ion-free at last follow-up. Of the 41 patients who
eceived both cycles of high-dose therapy, 18 are alive
nd disease free. Eighteen had disease progression at a
edian of 4 months (range: 1-64) posttransplant and
ll but 1 died from progressive disease. Five died from
onrelapse mortality.
Using an intent-to-treat analysis for all 46 patients
ncluded in the study, the 5-year estimate of OS,
rogression-free survival (PFS), and freedom from
rogression (FFP) were 54% (95%CI 40%-69%),
9% (95%CI 34%-63%), and 55% (95% CI 40%-
0%), respectively (Figure 1). In an analysis limited to
atients (n  41) who received the planned treatment
rogram according to the protocol, the estimated
igure 1. OS and PFS for the 46 patients who were enrolled in the
vtudy as intent to treat.-year OS, PFS, and FFP were 57% (95%CI 41%-
3%), 49% (95%CI 33%-64%), and 55% (95%CI
9%-71%), respectively (Figure 2). In a univariate
nalysis, we failed to identify any prognostic factors
hat predicted for transplant outcomes (Table 2).
eath/Toxicity
There were 2 early deaths resulting from regimen-
elated toxicities with 100-day mortality of 4%. One
atient died from sepsis at day 30 postsecond trans-
lant and the other patient who had received 2500
Gy of mediastinal irradiation before the second high-
ose TBI regimen died of interstitial pneumonitis.
hree other patients died of nonrelapse causes while
n remission because of adenocarcinoma (1), ruptured
neurysm (1), and cardiac event (1). Adenocarcinoma
as diagnosed at 7 months posttransplant in a 55-
ear-old patient with history of documented liver in-
olvement by HL. Another 58-year-old with prior
istory of hypertension died from a ruptured aortic
neurysm at 6 months posttransplant and a 40-year-
ld male with prior mediastinal radiation died from
ardiac arrest at 2 years posttransplant.
The transplant-related toxicities were similar to
istoric control patients who received single high-
ose therapy [5]. There were no cases of veno-occlu-
ive disease. Secondary malignancies occurred in 3
atients. One patient who relapsed 7 months after
andem transplant was subsequently found to have
herapy-induced myelodysplasia (MDS) at 28 months
fter transplant. He received TBI-based regimen fol-
owed by IFRT to minimantle ﬁeld posttransplant. He
nderwent matched unrelated donor transplant for
oth HD and MDS. There were 2 cases of solid
umors. One patient developed endometrial carci-
oma 4 years after ASCT and is currently in remission
fter total abdominal hysterectomy and bilateral sal-
ingo-oophorectomy. One patient who had liver in-
igure 2.OS and PFS for the 41 patients who underwent transplant
s planned.olvement by HL developed adenocarcinoma of the
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H. C. Fung et al.598iver at 7 months after transplant. He received TBI
ased high-dose regimen.
ISCUSSION
The experiences from City of Hope [5] and South-
est Oncology Group [7] have demonstrated that
ugmented BCV (BCNU 450 mg/m2, cyclophospha-
ide 100 mg/kg, and etoposide (VP-16) 60 mg/kg) or
TBI (1200 cGy)  VP-16 (60 mg/kg)  cyclophos-
hamide (100 mg/kg) are highly effective preparative
egimens for patients with advanced HL undergoing
SCT. Approximately 40% to 50% of unselected pa-
ients can achieve durable remission after transplant
ith very low transplant-related mortality (TRM).
rogressive disease after transplant accounts for most
f the treatment failures, in particular, for patients
ith poor risk features before ASCT. Multiple trans-
lant studies have identiﬁed adverse prognostic factors
hat predict transplant outcome such as early relapse
fter CR1, B symptoms at relapse, extra-nodal in-
olvement of lung or bone marrow at relapse, multiple
elapses, and more than minimal disease at the time of
ransplantation [4-8]. The estimated probability of
ong-term PFS after transplant for these patients was
pproximately 25% to 35%; therefore, an alternative
trategy is needed.
One possible approach to decrease the relapse
ates is to further intensify the conditioning regimens,
ither by increasing the dose of the individual drugs or
o add a fourth agent. Wheeler et al [10] performed a
hase I study using escalating doses of the drugs in the
BV combination. They concluded that the maxi-
um cumulative doses of Cytoxan, BCNU, and
P-16 that can be tolerated were 7200 mg/m2 of
yclophosphamide, 450 mg/m2 of carmustine, and
000 mg/m2 of etoposide. Further dose intensiﬁcation
as limited by toxicities and had not been shown to
mprove efﬁcacy. Reece et al [11] added cisplatin as
able 2. Univariate P-Values for PFS
Variable [relative to]
ex [female]
ge
Symptoms at diagnosis
Symptoms at BMT
BI vs. BCNU
tage at Dx (I/II vs. III vs. IV)
xtra-nodal disease at Dx
xtra-nodal disease at relapse
umber of prior chemotherapy regimens
hemosensitivity [resistant]
adiation at induction [NO]
rimary refractory vs. relapsed
I indicates conﬁdence interval; TBI, total body irridiation; BMTfourth agent to their intensiﬁed high-dose CBV tegimen (VP-16 2400 mg/m2, BCNU 500 mg/m2,
yclophosphamide 7200 mg/m2, and cisplatin 150
g/m2). Although the toxicities remained acceptable,
here was no evidence that this regimen was more
ffective than CBV alone. Different dose-intense reg-
mens had been tested but none of them has shown an
dvantage over the commonly used regimens such as
BV or BEAM (carmustine, etoposide, cytarabine,
nd melphalan). Minimal disease state before trans-
lant has been shown to be an important prognostic
actor for transplant outcomes [6,9]. However, repeat
ycles of conventional dose salvage chemotherapy may
ncrease drug resistance and increase transplant re-
ated toxicity. Melphalan is widely used as a compo-
ent of conventional salvage chemotherapy (MVP or
ini-BEAM) and as a preparatory regimen in stem
ell transplant (BEAM or BEM). Russell et al [12]
reated 20 HL patients with single high-dose melpha-
an (140-200 mg/m2) and stem cell support. All 20
atients had relapsed/refractory HL and were heavily
retreated by multiple chemotherapeutic regimens.
he overall response rate was 86%, with complete
emission and partial remission rate of 33% and 56%,
espectively. Twenty percent of patients achieved a
urable complete remission and the regimen was well
olerated.
Given the above background and the unfavorable
utcomes of patients with poor risk disease, we con-
ucted this pilot study to evaluate the safety and efﬁ-
acy of a tandem ASCT program for patients with
rimary progressive or poor risk recurrent HL. With
median follow-up of 5 years, the 5-year Kaplan-
eier estimate of OS and FFP were 57% and 55%,
espectively. The results reported in our study are
romising and compare favorably to historic controls
here the EFS were approximately 25% to 35% in
hese unfavorable patients. Because most relapses after
ransplant occurred within the ﬁrst 2 years of ASCT,
ur median follow-up of 5 years suggests that tandem
Hazard Ratio and 95% CI P Value
0.95 (0.62, 1.43) .7999
1.02 (0.98, 1.06) .3523
0.84 (0.54, 1.27) .4082
0.73 (0.48, 1.18) .1910
0.94 (0.63, 1.46) .7917
I/II vs. IV 1.36 (0.76, 2.46)
III vs. IV 0.58 (0.29, 1.11)
.8580
.2313
0.83 (0.55, 1.29) .3938
1.17 (0.64, 2.20) .6062
1.41 (0.72, 2.68) .3146
1.04 (0.55, 1.76) .8872
0.68 (0.43, 1.03) .0707
1.36 (0.89, 2.19) .1653
and marrow transplant.ransplant may induce long-term disease control and
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Tandem Autologous Stem Cell Transplantation 599ossibly “cure” in some patients despite the presence
f poor risk factors. Although many reported trans-
lant series had excluded patients who failed stem cell
ollection or progressed before transplant, we in-
luded all enrolled patients in our analysis to avoid
election bias. In this study, all patients who pro-
ressed after cycle 1 of high-dose melphalan devel-
ped disease progression shortly after cycle II high-
ose therapy. These subgroups of patients with highly
hemoresistant disease do not beneﬁt from high-dose
herapy and ASCT, and alternative treatment strategy
ill need to be developed for these patients.
The experiences of tandem high-dose therapy and
SCT have been previously reported by other inves-
igators using different approaches. Ahmed et al [13]
eported results of tandem ASCT in 45 patients with
efractory HL. With a median follow-up of 4 years,
he median survival was 45 months. However, it is
orth noting that only 55% of the patients received
oth planned cycles. Patients were ineligible for sec-
nd cycle because of toxicity or disease progression. In
ur present trial, 83% of patients completed the
lanned 2 cycles of high-dose therapy and none of the
atients were excluded from the second high dose
herapy because of transplant related toxicity. In
nother study reported by Brice et al [14,15], 72
atients with very unfavorable HL received 2 cycles
f high-dose therapy with stem cell rescue. The ﬁrst
ycle consisted of CBV  mitoxantrone (30 mg/m2)
nd the second cycle consisted of cytarabine (6 gm/m2),
elphalan (140 mg/m2) and TBI (12 Gy) or busul-
an (12 mg/m2). Seventy-two percent of patients
eceived both transplants with a response rate of 91%.
here were 2 toxic deaths from veno-occlusion dis-
ase and acute respiratory distress syndrome.
The Intergruppo Italiano Linfomi used a high-
ose sequential chemotherapy approach in 102 pa-
ients with refractory/relapsed HL [16]. At a median
ollow-up of 5 years, the 5-year event-free survival and
S for all patients were 53% and 64%, respectively. A
imilar approach was conducted by the German HL
tudy group for 102 patients with relapsed and refrac-
ory HL. With a median follow-up of 30 months,
reedom from second failure and OS for patients with
arly relapse were 59% and 78%, respectively [17].
The results of these studies suggest that patients
ith primary refractory HL or poor-risk relapsed HL
ay beneﬁt from a more intensive approach such as
igh-dose sequential therapy or tandem ASCT with
tem cell support with low toxicities. Nevertheless, the
avorable results from our study and similar studies
ould result from patient selection. In our study, we
elected patients with primary progressive HL and
atients with recurrent disease associated with 1 of the
ollowing poor risk factors: extra-nodal disease or
ymptoms at relapse or duration of initial response
12 months. Although, they are often reported asdverse prognostic factors, most of these studies in-
lude a heterogeneous patient population and small
umber of patients may complicate the interpretation.
large-scale phase II study followed by a phase III
andomized study will be required to conﬁrm the
esults.
Taken together, our data suggest that for patients
ith primary refractory or poor risk recurrent HL, a
andem AHCT is effective and well tolerated without
xcessive toxicities. The results compare favorably
ith the historic control of conventional single trans-
lant. To conﬁrm the encouraging results from this
ilot study, the Southwest Oncology Group is cur-
ently testing this approach in the cooperative group
etting.
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